Advances in Drug Delivery Systems for the Management of Metabolic Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 825

Special Issue Editors


E-Mail Website
Guest Editor
Departamento de Farmácia, Facultad de Ciencias, Universidad Nacional de Colombia, Cra. 30 45-03, Bogotá 111321, DC, Colombia
Interests: drug delivery system; microparticles; nanoparticles; self-emulsifying delivery; pharmacokinetics; extracts standardization; bioactive compounds
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Laboratory of Hormones & Signal Transduction, Departament of Biochemistry, Center of Biological Sciences, Campus Trindade, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil
2. Laboratory of Biochemistry and Pharmacology, Departament of Pharmacology and Physiology, Drug Research and Development Center (DRDC), Medical School, Federal University of Ceará, Rua Coronel Nunes de Melo, Fortaleza 60430-275, CE, Brazil
Interests: natural compounds; diabetes; infertility; cancer; central nervous system diseases; chronic diseases; medicinal plants; pain and analgesia
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit your original research articles and reviews to the Special Issue entitled “Advances in Drug Delivery Systems for the Management of Metabolic Diseases” in Pharmaceutics. Metabolic diseases, including diabetes, obesity, and hyperlipidemia, are increasingly prevalent worldwide and pose significant challenges to global health. The development of innovative drug delivery systems tailored for the effective management of these conditions is an area of growing scientific interest and importance. This Special Issue aims to bring together cutting-edge research and insights into this dynamic field, highlighting advancements that improve therapeutic efficacy, patient compliance, and safety.

This Special Issue seeks to provide a comprehensive platform for exploring the latest advancements in drug delivery systems, including synthetic drugs, secondary metabolites, and natural extracts. Research encompassing in silico, in vitro, in vivo studies, preclinical, and clinical trials is highly encouraged, emphasizing innovative formulations, nanotechnology, and controlled-release systems, among others.

In this Special Issue, we welcome original research articles and reviews including but not limited to the following topics:

  • Advanced drug delivery systems for synthetic and natural products targeting metabolic diseases.
  • Nanotechnology-based delivery approaches (e.g., nanoparticles, nano-emulsions, micelles).
  • Controlled-release and targeted delivery formulations for enhanced efficacy and safety.
  • Applications of in silico modeling for formulation optimization and drug-target interactions.
  • Preclinical and clinical studies on innovative delivery systems.
  • Delivery systems for secondary metabolites and extracts as therapeutic agents in metabolic disease management.
  • Pharmacokinetics and pharmacodynamics of novel formulations.

We look forward to your valuable contributions to this Special Issue. Let’s advance this crucial area of research together!

Prof. Dr. Diana Marcela Aragon Novoa
Prof. Dr. Fátima Regina Mena Barreto Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery systems
  • metabolic diseases
  • nanotechnology
  • synthetic drugs and natural extracts
  • preclinical and clinical studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1039 KiB  
Article
Self-Emulsifying Drug Delivery System Enhances the Antidiabetic Activity of Passiflora ligularis Leaf Extract
by Sandra M. Echeverry, Diana P. Rey, Ivonne H. Valderrama, Ingrid A. Rodriguez, Paula M. Sepúlveda, Bibiana Verlindo de Araujo, Fátima Regina Mena Barreto Silva and Diana Marcela Aragón
Pharmaceutics 2025, 17(6), 730; https://doi.org/10.3390/pharmaceutics17060730 - 31 May 2025
Viewed by 408
Abstract
Background/Objectives: Previous studies have shown that unformulated extracts of Passiflora ligularis leaves exhibit promising antidiabetic activity. This research aimed to demonstrate that formulating the extract into a self-emulsifying drug delivery system (PLE-SEDDS) enhanced its antidiabetic activity in a high-fat-diet/streptozotocin-induced diabetic mouse model. Methods [...] Read more.
Background/Objectives: Previous studies have shown that unformulated extracts of Passiflora ligularis leaves exhibit promising antidiabetic activity. This research aimed to demonstrate that formulating the extract into a self-emulsifying drug delivery system (PLE-SEDDS) enhanced its antidiabetic activity in a high-fat-diet/streptozotocin-induced diabetic mouse model. Methods: Blood glucose levels (BGLs) of diabetic mice were monitored during 21 days of oral administration of P. ligularis extract (PLE) and PLE-SEDDS. Control groups included metformin (positive control), vehicle, and SEDDS vehicle (negative controls). The animals underwent an oral glucose tolerance test (OGTT). The oxidative stress markers superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation quantified by malondialdehyde (MDA) levels were measured in the kidney, liver, and pancreas, complemented with histopathological analysis. Additionally, plasma lipid profile parameters were evaluated. Results: The PLE-SEDDS formulation demonstrated superior efficacy compared to the PLE extract in improving antidiabetic outcomes. Animals treated with PLE-SEDDS exhibited a minimal increase in blood glucose levels (11.5%) during the OGTT, compared to 27.4% with PLE and over 77% in the vehicle groups. PLE-SEDDS also showed greater enhancement of SOD and CAT activity, along with a more pronounced reduction in MDA levels, indicating stronger protection against oxidative stress. Histological analysis revealed significant preservation of pancreatic islets, and lipid profile analysis showed greater reductions in triglycerides, cholesterol, and LDL-C, alongside increased HDL-C levels. Conclusions: Altogether, these findings suggest that PLE-SEDDS exhibits superior antihyperglycemic, hypolipidemic, and antioxidant effects compared to the unformulated extract, making this novel formulation a promising option for treating type 2 diabetes mellitus. Full article
Show Figures

Figure 1

Back to TopTop